Enanta Pharmaceuticals
ENTA
179 hedge funds and large institutions have $1.4B invested in Enanta Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 65 increasing their positions, 49 reducing their positions, and 11 closing their positions.
300% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 11
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
33% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 49
27% more capital invested
Capital invested by funds: $1.1B → $1.4B (+$301M)
22% more funds holding
Funds holding: 147 → 179 (+32)
3.51% less ownership
Funds ownership: 95.94% → 92.44% (-3.5%)
88% less call options, than puts
Call options by funds: $2.86M | Put options by funds: $23.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$14.4M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$13M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$12.7M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$10.7M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$5.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$61.2M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$33.1M |
| 3 |
KAM
Krensavage Asset Management
New York
|
-$29.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$13.7M |
| 5 |
BlackRock
New York
|
-$9.7M |
ENTA Hedge Fund Activity: Q4 2021 in Review
179 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2021, worth a combined $1.4B — up 27% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new ENTA positions and 11 closed out — a net gain of 33 holders — while 65 added to existing stakes and 49 trimmed.
The largest buyer was Invesco, adding an estimated $14.4M. The largest seller was Armistice Capital, cutting an estimated $61.2M.
- 179 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2021, up from 147 in Q3 2021.
- Funds reported $1.4B of Enanta Pharmaceuticals stock for Q4 2021, up 27% quarter-over-quarter.
- 44 funds opened new Enanta Pharmaceuticals positions in Q4 2021 and 11 closed out, a net change of +33 holders.
- The largest Enanta Pharmaceuticals buyer in Q4 2021 was Invesco, an estimated $14.4M added.
- The largest Enanta Pharmaceuticals seller in Q4 2021 was Armistice Capital, an estimated $61.2M sold.
Based on aggregated 13F filings for Q4 2021.